click enter text
dhr trend confirm achiev investor feedback
concentr organ guid impli slowest core growth
sinc prior full impact cphd/idt commerci scale-
bioprocess market recoveri strike conserv
even consid bp shift project/ord time japan
biolog regardless back half impli top
comp suggest ex-dent ex-g franchis track
well expect core embed cushion macro
see caus concern import news
recent day result accumul
posit signal bioprocess given implic ge ls pro-forma
make materi chang core model slightli rais ge
pro-forma number rais pt remain outperform
pro-forma ep outlook leverag biolog rel macro insul
trade fundament data
upsid target
neg signal dental outlin call price growth
weak compound growth hit new low guidanc
weak valid dilig impact sector consolid
flag dental preview dental industri launch note
rais question advers price/mix xray/pdco/hs
lack clariti spark io time minor posit
concern hardwar weak tool flag
note instrument trend slow tool less critic tmo/
confirm leverag privat appli lab point
rel pressur sciex growth step exhibit
tmo instrument franchis compani higher equipment/appli
hold better vs small molecul pharma applied/industrial/food
academ dx strength confirm issu isol
guidance/ep bridg revis ep guidanc midpoint
 neg revis high end reflect impact
non-control interest follow envista ipo addit fx
headwind compar prior guidanc partial off-set
organ ebit beat increment net interest incom benefit
lower interest rate debt cash proce ipo
wolf research pleas
announc inaugur healthcar
confer ny novemb
click regist view
agenda
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
result wolf model chang
exhibit result vs wolf estimate consensu
note lower ep reflect shift cap deploy benefit
page
mnepscon organ changelif life gross oper interest net/cont share non-gaap gross bp tax bpsnet bpsprior price-to-earnings premium tool median median medianannu guidancea growth ex itemsgaap guidancea growth ex itemsgaap revenu profit incom mm dilut share outstand
sartoriu earlier
exhibit forma estim deal
ge deal updat provid updat ge
deal deal expect close
updat announc divestitur
week
manag updat accret estim
point benefit lower interest rate
initi accret guidanc
manag also note ge busi
strong start year divestitur
expect modest headwind
revenu ge busi
divestitur sartoriu surpris one
quarter delay deal close time
bioprocess space quit consolid make
continu littl concern around likelihood
acquisit ge ls close
concentr differ segment
bioprocess product chain divestitur
legaci pll line primarili chromatographi hardwar resin aggreg growth asset sold like near
market announc morn like appeas minor regulatori concern delay
expect close year-end like incorpor addit file work may
delay determin asset sale necessari view remain upsid driver
rel guidanc accret ge asset bioprocess result morn rais bioprocess
outlook higher end specifi rang support view divestitur roughli
revenu unconcern dilut perspect
exhibit organ sale growth segment
page
exhibit organ growth trend product line
page
page
yieldfcf compound-annual-growth-rate ebitda compound-annual-growth-rate ev-ebitda vs estimate ebitda compound-annual-growth-rate tool ntm price-to-earnings ratio median price-to-earnings premium compound-annual-growth-rate
note figur million unless state per-shar term
page
note figur million unless state per-shar term
page
 sale detail mn adjust sell day revenu wr organ bp bpsm estimate bp bp bp bp bp bp bp bpsother estimate bp bp bp bp bp bp bp bp bp bp bp wr organ bp bpsm bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bpsother bp bp bp bp bp bp bp bp bp bp bp bp bp bp wr organ bp bpsm bp bp bp bp bp bp bp bpsother bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp wr organ bp bp bp bp bp bp bp bp bp bp bp bp bp bpsother bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp
